PCRX Q3 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$169M+2.8% YoY

Gross Profit

$130M76.9% margin

Operating Income

-$140M-82.8% margin

Net Income

-$143M-85.1% margin

EPS (Diluted)

$-3.11

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

$54M

Free Cash Flow

$50M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$772M

Stockholders' Equity

$750M

Cash & Equivalents

$246M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169M	$164M	+2.8%
Gross Profit	$130M	$124M	+4.5%
Operating Income	-$140M	$18M	-887.4%
Net Income	-$143M	$11M	-1421.3%

Revenue Segments

Product

$168M51%

EXPAREL

$132M40%

ZILRETTA

$28M9%

Bupivacaine Liposome Injectable Suspension

$2M0%